Case Studies and Literature Review of Francisella tularensis-Related Prosthetic Joint Infection.

France Francisella tularensis bacteria prosthetic joint infection tularemia zoonoses zoonotic disease

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
06 2023
Historique:
medline: 22 5 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

Tularemia is a zoonotic infection caused by Francisella tularensis. Its most typical manifestations in humans are ulceroglandular and glandular; infections in prosthetic joints are rare. We report 3 cases of F. tularensis subspecies holarctica-related prosthetic joint infection that occurred in France during 2016-2019. We also reviewed relevant literature and found only 5 other cases of Francisella-related prosthetic joint infections worldwide, which we summarized. Among those 8 patients, clinical symptoms appeared 7 days to 19 years after the joint placement and were nonspecific to tularemia. Although positive cultures are typically obtained in only 10% of tularemia cases, strains grew in all 8 of the patients. F. tularensis was initially identified in 2 patients by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; molecular methods were used for 6 patients. Surgical treatment in conjunction with long-term antimicrobial treatment resulted in favorable outcomes; no relapses were seen after 6 months of follow-up.

Identifiants

pubmed: 37209668
doi: 10.3201/eid2906.221395
pmc: PMC10202857
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118-1126

Références

J Bacteriol. 2004 Sep;186(17):5808-18
pubmed: 15317786
Virulence. 2013 Nov 15;4(8):833-46
pubmed: 24225421
Clin Microbiol Rev. 2002 Oct;15(4):631-46
pubmed: 12364373
Am J Med. 2014 Aug;127(8):786.e7-786.e10
pubmed: 24662624
Int J Syst Bacteriol. 1994 Jan;44(1):38-46
pubmed: 8123561
Microorganisms. 2020 Jul 28;8(8):
pubmed: 32731606
BMJ Case Rep. 2017 Oct 11;2017:
pubmed: 29025776
JAMA Surg. 2017 Aug 01;152(8):784-791
pubmed: 28467526
Appl Environ Microbiol. 2004 Jun;70(6):3733-5
pubmed: 15184180
Rev Chir Orthop Reparatrice Appar Mot. 2007 Oct;93(6):582-7
pubmed: 18065867
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
Emerg Microbes Infect. 2019;8(1):1027-1042
pubmed: 31287787
Nat Rev Microbiol. 2004 Dec;2(12):967-78
pubmed: 15550942
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
J Antimicrob Chemother. 2018 Mar 1;73(3):687-691
pubmed: 29253157
Bosn J Basic Med Sci. 2016 Jan 15;16(2):132-8
pubmed: 26773181
Infect Dis Clin North Am. 2017 Jun;31(2):237-252
pubmed: 28366224
Int J Infect Dis. 2019 Apr;81:128-136
pubmed: 30772469
Orthopedics. 2020 Jan 1;43(1):e54-e56
pubmed: 31269216
Emerg Infect Dis. 2006 Nov;12(11):1799-801
pubmed: 17283646
Euro Surveill. 2014 Nov 13;19(45):20956
pubmed: 25411688
Clin Infect Dis. 1999 Dec;29(6):1589-91
pubmed: 10585830
Lancet Infect Dis. 2016 Jan;16(1):113-124
pubmed: 26738841
Clin Infect Dis. 2011 Nov;53(10):e133-41
pubmed: 22002987
Future Microbiol. 2010 Apr;5(4):649-61
pubmed: 20353304
Microorganisms. 2021 Jun 28;9(7):
pubmed: 34203503
Lancet Infect Dis. 2016 Dec;16(12):e288-e303
pubmed: 27816414
J Clin Microbiol. 2019 Jul 26;57(8):
pubmed: 31189580
Front Cell Infect Microbiol. 2017 Apr 11;7:122
pubmed: 28443249
Lancet. 2018 Nov 3;392(10158):1672-1682
pubmed: 30496082
Antimicrob Agents Chemother. 2000 Dec;44(12):3428-31
pubmed: 11083651
J Clin Microbiol. 2003 Dec;41(12):5492-9
pubmed: 14662930
Front Cell Infect Microbiol. 2014 Mar 28;4:40
pubmed: 24734221
N Engl J Med. 2018 Jul 12;379(2):197-199
pubmed: 29996079
Euro Surveill. 2004 Dec;9(12):27-28
pubmed: 29183485
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
J Microbiol Methods. 2020 Oct;177:106055
pubmed: 32918935
J Infect Dev Ctries. 2014 Oct 15;8(10):1277-84
pubmed: 25313604
Lancet. 2018 Nov 3;392(10158):1662-1671
pubmed: 30496081
Expert Rev Anti Infect Ther. 2008 Apr;6(2):231-40
pubmed: 18380605
Lancet. 2016 Jan 23;387(10016):386-394
pubmed: 26135702
Infect Dis Clin North Am. 2018 Dec;32(4):843-859
pubmed: 30241717

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH